Tborges, if only the Panzem affect on p53 was not a u-shaped curve. IMO, correct u-shaped doses are hard to hit targets in humans. You would need some sort of feedback system to tell you when the dose is at the optimum level.
"The recent publication of preclinical results for ENMD 2076 in TNBC cancer lines revealed that activity was greater in those cell lines with increased P53 expression."
Tborges, building on your idea of improving ENMD 2076 effectiveness I would like to suggest the Gendicine & ENMD 2076 combo. As you noted, ENMD 2076 was more effective in cancer cell lines with increased p53 suppresser genes expression. Then why not use Gendicine (a p53 gene therapy treatment) to improve the outcome of ENMD 2076.
I found Gendicine on a China cancer therapy site. It's a gene therapy that introduces p53 genes into cancer via a virus. It's also only done in China.
How about urinary agiostatin as a biomarker for ENMD 2076 use.
ENMD 2076 appeared to work better in tumors with high P53 expression and agiostatin has been shown to increase P53 levels and angiostatin is a natural anti-agiogenic molecule associated with some tumors. Maybe high levels of urinary angiostatin found in a patient may indicate higher tumor angiostatin levels and P53 levels. Maybe urinary angiostatin biomarker could be added to the biomarker profile someday predicting ENMD 2076 chances of success.
Just a thought, Aaron
“Within the TNBC subset itself, cell lines with a p53 mutation and increased p53 expression were more sensitive to the cytotoxic and pro-apoptotic effects of ENMD-2076 exposure than cell lines with decreased p53 expression. This information provides the basis for a predictive biomarker strategy to explore in future clinical trials with ENMD-2076.”
“Furthermore, [angiostatin] K1-3, K1-4 or K1-4.5 increased the expression of p53 protein and its downstream effectors, enhanced FasL-mediated signaling pathways, and decreased activation of AKT.”
“Levels of [angiostatin] AS are elevated in the urine of patients with [epithelial ovarian cancer] EOC and may be of diagnostic and/or prognostic clinical importance. Further studies of uAS as a biomarker for EOC alone or in combination with other markers are warranted.”
Market Data 
Markets 
AI
